Arteriocyte Medical Technologies — Cyborg Score 4/10
Weak
Point-of-care cell therapy devices
Strategic Profile
Arteriocyte pioneered bedside cell therapy systems including the Magellan platform for rapid production of platelet-rich plasma and bone marrow-derived cellular concentrates. The company has pursued clinical development in orthopedic trauma and critical limb ischemia with partnerships including the U.S. Army Institute of Surgical Research.
Cyborg Score Rationale
The company was acquired by ISTO Technologies in October 2016 and now operates as Isto Biologics. Recent activity and current market position are unclear from available public sources. Limited financial and operational transparency post-acquisition limits confidence.
Top Insights
Magellan system is FDA 510(k) cleared for point-of-care production of platelet-rich plasma and bone marrow concentrate
Acquired by ISTO Technologies in October 2016 and integrated into Isto Biologics platform
Original company (Arteriocyte Inc.) founded in 2004 as spinout from Case Western Reserve University collaboration
Clinical focus includes orthopedic trauma, critical limb ischemia, and vascular disease applications
Named Competitors
InvitroGen/Gibco — Cell culture and regenerative medicine research products
Zimmer Orthopedic Biologics — Orthopedic and regenerative biology solutions
RTI Biologics — Regenerative tissue products for surgery
Recent Developments
(June 2011) Cooperative Research and Development Agreement (CRADA) signed with U.S. Army Institute of Surgical Research for cellular therapies in orthopedic trauma
(October 2016) Acquired by ISTO Technologies and integrated into Isto Biologics
Open the full interactive Arteriocyte Medical Technologies report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.